TheEdgeResearch
Home / Stocks / LTGO

Latigo Biotherapeutics Inc. (LTGO)

NASDAQ Healthcare Medical - Pharmaceuticals
$13.00 ▼ -1.81%
Market Cap
$782.0M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
0.00
52-Wk Range
10.24-25.93
CEO
Todd N. Smith
Country
US
Currency
USD

Latigo Biotherapeutics Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Thousand Oak, CA, US. The stock last traded at $13.00, down 1.81% on the session, giving a market capitalisation of $782.0M. On trailing twelve-month figures it carries a trailing P/E of -5.52, a net margin of 0.0%. Its beta of 0.00 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-5.52
Price / Sales
0.00
Price / Book
1.25
EV / EBITDA
-3.54
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
29.11
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
66
IPO date
2026-08-07
Headquarters
Thousand Oak, CA, US
About Latigo Biotherapeutics Inc.

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

Comparable companies

Latigo Biotherapeutics Inc. is most often compared with the following Healthcare names:

COLLPCRXSCLX
More research on LTGO
LTGO technical analysis LTGO TheEdge Score Compare against peers
Open full interactive analysis & DCF →